OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Arch Therapeutics Stock (OTCMKTS:ARTH) 30 days 90 days 365 days Advanced Chart Get Arch Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.00▼$0.2652-Week Range N/AVolume5,998 shsAverage Volume4,068 shsMarket Capitalization$4,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Read More… Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTH Stock News HeadlinesArch Therapeutics (OTCMKTS:ARTH) & Profound Medical (NASDAQ:PROF) Head-To-Head AnalysisMay 13, 2025 | americanbankingnews.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)October 1, 2024 | globenewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 22, 2025 | Porter & Company (Ad)Chicago biotech-focused VC firm Arch Venture Partners closes $3 billion fundSeptember 27, 2024 | bizjournals.comArch Therapeutics, Inc. (ARTH)August 21, 2024 | finance.yahoo.comArch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug ToxinsAugust 2, 2024 | tmcnet.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)May 6, 2024 | globenewswire.comArch Therapeutics Secures $750K Prepayment for StockFebruary 8, 2024 | msn.comSee More Headlines ARTH Stock Analysis - Frequently Asked Questions How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01. How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings7/23/2020Today5/21/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,980,000.00 Net Margins-8,257.70% Pretax Margin-8,257.70% Return on EquityN/A Return on Assets-730.22% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.01 Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($2.43) per share Price / BookN/AMiscellaneous Outstanding Shares4,742,000Free Float4,529,000Market Cap$4,000.00 OptionableNot Optionable Beta4.02 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (OTCMKTS:ARTH) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arch Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.